The functional integrity of the serpin domain of C1 inhibito depends on
the unique N-terminal domain, as revealed by a pathological mutant
Bos, I.G.A.; Lubbers, Y.T.P.; Roem, D.; Abrahams, J.P.; Hack, C.E.; Eldering, E.
Citation
Bos, I. G. A., Lubbers, Y. T. P., Roem, D., Abrahams, J. P., Hack, C. E., & Eldering, E. (2003).
The functional integrity of the serpin domain of C1 inhibito depends on the unique
N-terminal domain, as revealed by a pathological mutant. Journal Of Biological Chemistry,
278(32), 29463-29470. doi:10.1074/jbc.M302977200
Version:
Not Applicable (or Unknown)
License:
Leiden University Non-exclusive license
Downloaded from:
https://hdl.handle.net/1887/50032
The Functional Integrity of the Serpin Domain of C1-inhibitor
Depends on the Unique N-terminal Domain, as Revealed by a
Pathological Mutant*
Received for publication, March 24, 2003, and in revised form, May 21, 2003 Published, JBC Papers in Press, May 27, 2003, DOI 10.1074/jbc.M302977200
Ineke G. A. Bos‡§, Yvonne T. P. Lubbers‡, Dorina Roem‡, Jan Pieter Abrahams¶, C. Erik Hack‡储,
and Eric Eldering**
From the ‡Department of Immunopathology, Sanquin Research at CLB, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, 1066 CX Amsterdam, the¶Leiden Institute of Chemistry, Biophysical Structural Chemistry, 2333 CC Leiden, the储Department of Clinical Chemistry, Free University Medical Center, 1081 HV Amsterdam, and the **Department of Experimental Immunology, Academic Medical Center, University of Amsterdam,
1105 AZ Amsterdam, The Netherlands
C1-inhibitor (C1-Inh) is a serine protease inhibitor (serpin) with a unique, non-conserved N-terminal do-main of unknown function. Genetic deficiency of C1-Inh causes hereditary angioedema. A novel type of mutation (⌬3) in exon 3 of the C1-Inh gene, resulting in deletion of Asp62-Thr116in this unique domain, was encountered in
a hereditary angioedema pedigree. Because the domain is supposedly not essential for inhibitory activity, the unexpected loss-of-function of this deletion mutant was further investigated. The ⌬3 mutant and three addi-tional mutants starting at Pro76, Gly98, and Ser115,
lack-ing increaslack-ing parts of the N-terminal domain, were pro-duced recombinantly. C1-Inh76 and C1-Inh98 retained normal conformation and interaction kinetics with tar-get proteases. In contrast, C1-Inh115and⌬3, which both lack the connection between the serpin and the non-serpin domain via two disulfide bridges, were com-pletely non-functional because of a complex-like and multimeric conformation, as demonstrated by several criteria. The ⌬3 mutant also circulated in multimeric form in plasma from affected family members. The C1-Inh mutant reported here is unique in that deletion of an entire amino acid stretch from a domain not shared by other serpins leads to a loss-of-function. The deletion in the unique N-terminal domain results in a “multim-erization phenotype” of C1-Inh, because of diminished stability of the central-sheet. This phenotype, as well as the location of the disulfide bridges between the ser-pin and the non-serser-pin domain of C1-Inh, suggests that the function of the N-terminal region may be similar to one of the effects of heparin in antithrombin III, main-tenance of the metastable serpin conformation.
The autosomal dominant disease hereditary angioedema (HAE)1is caused by functional deficiency of C1-inhibitor
(C1-Inh) (1). C1-Inh is the major inhibitor of C1s and C1r of the classical pathway of complement and also an inhibitor of the contact system proteases, factor XIIa, kallikrein, and factor XIa (2–9). A lack of this inhibitor may result in recurrent episodes of acute, local, circumscribed edema of the skin or mucosa. The most serious and potentially life-threatening manifestation of the disease is laryngeal edema (10). HAE is inherited as an autosomal dominant trait; affected individuals are heterozy-gous. Based on the relative levels of functional and antigenic C1-Inh, two types of HAE have traditionally been described. In type I (⫾ 85% of HAE patients), defective expression of one allele results in low antigenic and functional levels. In type II (⫾15% of HAE patients), levels of functional C1-Inh are low, but C1-Inh antigen levels are normal because of the presence of a dysfunctional mutant protein. Although heterozygosity would suggest functional C1-Inh levels of around 50% in HAE, these levels are lower than 50%, typically 5–30%, which is ascribed to increased C1 activation and C1-Inh consumption (10, 11). However, the description of low levels of non-func-tional C1-Inh mutants in patients with type I HAE has dem-onstrated that the distinction between types I and II HAE is not absolute (12). For example, low levels of dysfunctional mutant protein may occur in cases where the mutation also leads to defective protein secretion (12, 13). Many different mutations can lead to dysfunctional C1-Inh, as has recently been reviewed (14).
C1-Inh is a human plasma glycoprotein and a member of the serine protease inhibitor (serpin) family to which antithrombin III (ATIII), plasminogen activator inhibitor 1, and ␣1-antitryp-sin also belong. Serpins are suicide inhibitors that function as a set mousetrap by forming highly stable complexes with their cognate proteases. In its active form, a serpin has a metastable structure with a flexible reactive site loop that protrudes from the core of the molecule, the central-sheet. The key residues P1-P1⬘ form the reactive site, a pseudosubstrate for the target protease. Upon proteolytic attack on this bond, the reactive site loop is pulled into the central -sheet, inducing a dramatic conformational change that results in the formation of covalent complexes between inhibitor and protease (15, 16). Recent crys-tallographic studies support the idea that during complex
for-* Funded by the Netherlands Foundation for Preventive Medicine Grant 28-2274 and by a Landsteiner blood transfusion research grant. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Sanquin Research at CLB, Dept. of Immunopathology, Plesmanlaan 125, 1066 CX Amster-dam, The Netherlands. Tel.: 31-20-5123171; Fax: 31-20-5123170; E-mail: i.bos@sanquin.nl.
1The abbreviations used are: HAE, hereditary angioedema; C1,
com-plement factor 1; C1-Inh, C1 esterase inhibitor, inhibitor of C1, coagu-lation factors XIIa, XIa, and kallikrein; WT, wild type; C1-Inh76,
C1-Inh98, and C1-Inh115, C1-Inh deletion mutants starting at amino acid
76, 98, and 115, respectively;⌬3 C1-Inh, C1-Inh mutant lacking amino acids 62–116; ATIII, antithrombin III; mAB, monoclonal antibody; RII, mAb reacting with all forms of C1-Inh; Kok-12, mAb reacting with cleaved and complexed C1-Inh; ELISA, enzyme-linked immunosorbent assay.
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org
29463
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
mation the catalytic triad of the protease becomes distorted, which may explain the remarkable stability of the complex (17–19). Because mutations in the conserved flexible hinge region convert most inhibitory serpins into substrates, it is currently believed that the velocity of this conformational change determines whether complex formation and inhibition occur or whether the serpin is cleaved and the protease re-leased (20 –24). Indeed, type II HAE may result from mutations in this hinge region of C1-Inh (25, 26).
The conformational flexibility of serpins is also demon-strated by the existence of additional, biologically relevant conformations that are more stable. One of these is a latent, inactive form, adopted naturally by plasminogen activator inhib-itor 1 and ATIII, in which the uncleaved reactive site loop is inserted into-sheet A, and the C-terminal peptide stalk and strand 1C are reoriented along the side of the molecule (27, 28). In ATIII and␣1-AT this latent state can be artificially induced (29), but artificial formation of latent C1-Inh has never succeeded (30, 31). Secondly, non-covalent multimerization can occur upon denaturation, heating, or proteolysis at certain sites in the reac-tive site loop (32, 33). Also, several disease-associated mutants of C1-Inh, ATIII, and ␣1-AT have this multimeric conformation (15), in some cases leading to accumulation of huge intracellular protein aggregates and loss of cellular function in diseases like emphysema (reviewed by Lomas and Carrell, Ref. 34).
Point mutations causing spontaneous multimerization can be located in diverse regions: in or near the hinge (29, 35, 36), near a conserved hydrophobic pocket at the C terminus (13), in helix B at a site predicted to play a role in the opening of -sheet A (37, 38), and near helix F which overlies -sheet A (39, 40). Conformational changes associated with latency or multimerization may result from similar structural causes, as demonstrated by ATIII-Rouen VI, in which a single point mu-tation results in the formation of latent monomers or multim-ers, depending on temperature (39).
Next to its canonical serpin domain, C1-Inh has a unique N-terminal domain of 116 amino acids. Two disulfide bridges linking cysteine 101 to cysteine 406 and cysteine 108 to cys-teine 183 connect the N-terminal to the serpin domain (41). Reduction of these disulfide bonds in the intact serpin reduces its conformational stability and induces a latent conformation by auto-insertion of the reactive site loop into the central A -sheet (42). The N-terminal domain is unique for C1-Inh, and its exact function is unknown. Its first 98 residues were shown not to be essential for complex formation (43). Here, we de-scribe a novel type of mutation in the C1-Inh gene that sheds additional light on the function of this domain. The mutation, detected in a Dutch HAE pedigree, involves a deletion of 165 base pairs in exon 3 of the C1-Inh gene, leading to loss of amino acids 62 to 116. Although located in the non-serpin domain, the deletion resulted in loss of functional C1-Inh. The unique fea-tures of this pathological C1-Inh mutant prompted investiga-tion of the structural basis for the phenotype. Unexpectedly, the results revealed that the cysteine-containing fragment of the N-terminal domain of C1-Inh stabilizes the serpin domain by tethering the central-sheet via disulfide bridges. Thus, the reactive site loop is prevented from spontaneous insertion, reminiscent of one of the roles played by heparin in ATIII.
MATERIALS AND METHODS
Materials—[35
S]Methionine and 14
C-methylated protein markers were obtained from the Radiochemical Center (Amersham Biosciences). Biotin was from Pierce (Rockford, IL) and coupled to proteins according to the manufacturer’s instructions. Purified human plasma C1-Inh was a gift from Behringwerke (Marburg, Germany). Dithiothreitol and soy-bean trypsin inhibitor were purchased from Sigma; N-ethylmaleimide was purchased from BDH Biochemicals (Poole, UK). C1s for kinetic assays was purchased from Calbiochem (La Jolla, CA). Human factor
XIIa and kallikrein were purchased from Kordia (Leiden, the Nether-lands). Biotinylated polyclonal rabbit antibodies against human C1-Inh and the monoclonal antibodies (mAb) RII (against human C1-Inh) and Kok12 (specific for cleaved or complexed human C1-Inh) have been described before (44, 45). C1s for ELISAs was purified and biotinylated as described before (44). Streptavidin coupled to polymerized horserad-ish peroxidase was obtained from Sanquin (Dept. of Immune Reagents, Amsterdam, The Netherlands). Streptavidin coupled to monomeric horseradish peroxidase was obtained from Amersham Biosciences.
Patient DNA Purification and Plasma Parameters—Blood samples
were collected in siliconized vacutainer tubes (BD PharMingen). Soy-bean trypsin inhibitor (100g/ml), benzamidine (10 mM), and EDTA (10 mM) were added to prevent in vitro activation of the complement and contact systems. Tubes were centrifuged at 1,300⫻ g for 10 min, and plasma was aliquoted and stored at⫺70 °C until testing. Cells were collected and genomic DNA was purified according to the high salt precipitation protocol (46). Affected members were investigated for C1-Inh and C4 as reported previously (47) or ELISAs were utilized as described below.
PCR, Plasmid Construction, and Protein Expression—PCR on
genomic DNA (0.5g) was performed with primers (0.5 M) flanking exon 3 of the C1-Inh gene (28 cycles of 30 s, 90 °C; 60 s, 56 °C; 90 s, 72 °C). Forward primer, 5⬘-CTGACTATCCCTCATCTTC-3⬘; reverse primer, 5⬘-TTAGTGGCTGCGACCTTAT-3⬘. 5⬘-ends correspond with nucleotides 1951 and 2947, respectively, of the published C1-Inh gene sequence (48, 49). Wild-type and mutant PCR products were purified from agarose gels, subcloned in a T-tailed vector (Promega), and two independent clones were sequenced (USB, Cleveland, OH). Subcloning of relevant fragments was done by digestion with BamHI and EcoNI and insertion into the corresponding sites in the C1-Inh expression plasmid (50). COS-1 cell transfection, metabolic labeling, immunopre-cipitation, and SDS-PAGE were done as described before (13, 50). PCR and subcloning for production of the N-terminal deletion mutants in
Pichia pastoris was performed as described. Primers were designed that
started at amino acid 76, 98, and 115 of C1-Inh according to the numbering of Bock et al. (41) and enabled subcloning of the mutant gene in the plasmid for expression and secretion by P. pastoris. Transforma-tion of the P. pastoris strain GS115 and C1-Inh expression were per-formed as described before (51).
SDS-PAGE and Western Blotting—Electrophoresis was performed
on Bio-Rad Mini Protean II and Hoefer SE600 systems. Immunopre-cipitation of plasma samples or [35S]methionine-labeled COS media
was done with mAbs coupled to Sepharose 4B (Amersham Biosciences). Western blotting of HAE and normal plasma was performed by first adsorbing plasma samples (20l) onto mAb RII-Sepharose overnight, followed by five washes with phosphate-buffered saline containing 0.1% (w/v) Tween 20 (PT) and dissociation of bound C1-Inh by boiling in non-reducing sample buffer. Samples were electrophoresed on 7.5% gels and transferred to nitrocellulose. Blots were blocked with 0.4% (w/v) skimmed milk powder in phosphate-buffered saline and incubated with rabbit polyclonal anti-C1-Inh antibodies (2g/ml) for 2 h, followed by a 1-h incubation with peroxidase-conjugated horse polyclonal anti-rabbit antibodies (1:1000, Sanquin). Blots were developed with chemolumines-cence reagents from Amersham Biosciences.
Reduction and Alkylation of C1-Inh—Plasma C1-Inh (1 mg/ml) was
incubated for 30 min at room temperature with 100 mMdithiothreitol and subsequently with 250 mMN-ethylmaleimide to irreversibly
alkyl-ate the free cysteines. A control sample was trealkyl-ated with 250 mM
N-ethylmaleimide only. This preparation was dialyzed twice against a
100-fold excess of phosphate-buffered saline.
ELISAs—C1-Inh antigen was detected with an ELISA modified from
a radioimmunoassay (45, 52) as described earlier (53). Functional hu-man C1-Inh was detected as described (54). Briefly, C1-Inh was bound to solid-phase mAb RII against human C1-Inh and detected with bioti-nylated C1s. Notably, this assay is an end-stage, and not a kinetic, assay that measures the number of functional C1-Inh molecules rather than the kinetics of the interaction between C1s and C1-Inh. Confor-mationally changed C1-Inh was measured in an ELISA system with the mAb Kok12 as coating antibody. This mAb reacts with neo-epitopes exposed on complexed or cleaved C1-Inh. C1-Inh multimers were de-tected in an ELISA with mAb RII both as coating and as detecting antibody. PT was used as the buffer for all incubation steps in the ELISAs.
Kinetics of the Interaction between C1-Inh and Target Proteases—The
interaction between C1-Inh and C1s, coagulation factor XIIa, or kal-likrein was studied with the method of progress curves as described before (55). Experiments were performed twice in triplicate with similar results.
C1-Inh Metastability Depends on Unique N-terminal Domain
29464
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
Heat Stability—Culture supernatants containing normal or mutant
C1-Inh were incubated for 2 h at different temperatures, followed by centrifugation at 10,000⫻ g for 20 min. Antigen remaining in solution was measured in an ELISA for C1-Inh antigen.
Sucrose Density Gradient Centrifugation—Plasma samples (200l)
were loaded onto 5–25% (w/v) sucrose gradients in phosphate-buffered saline and centrifuged at 35,000 rpm at 4 °C for 16 h. Fractions were tested in ELISAs for C1-Inh antigen or multimers. Plasma fractions were also tested for C1-Inh, IgG, and IgM on an automated nephelom-eter (Behringwerke) as a reference for the molecular mass of C1-Inh species.
RESULTS
C1-inhibitor Protein and DNA Sequence of the Patient—The index patient had a typical history of HAE and was initially classified as a type I HAE based on levels of functional and antigenic levels of C1-Inh (17% both) and low C4 levels (30 mg/l). However, upon analysis by immune precipitation and immunoblotting, plasma from a member of the affected family appeared to contain low levels of an aberrant, low molecular mass form of C1-Inh of about 70 kDa, which was smaller than the intact and cleaved forms C1-Inh of 104 kDa and 97 kDa, respectively, which naturally occur in human plasma (Fig. 1). DNA sequencing of the pedigree, with primers flanking exon 3 of the C1-Inh gene, yielded an anomalous, specific PCR frag-ment. In addition to the normal fragment of 997 base pairs, a shorter fragment of⬃830 base pairs was observed that was cloned and sequenced (Fig. 2, a and b; GenBankTMAY291075).
It appeared that a deletion of 165 base pairs within the coding sequence of exon 3 had occurred. As is virtually always the case in HAE, the index patient was heterozygous for this deletion (Fig. 2a). Exon 3 of the C1-Inh gene codes for part of the signal sequence, the entire NH2-terminal domain, and part of the
serpin domain of C1-Inh. The deleted part is peculiar in nucle-otide (27% A, 44% C, 12% G and 16% T) sequence. Many A/C-rich direct repeats of up to 11 nucleotides are present, which may have caused the deletion to occur. In addition, it contains Cys101and Cys108, which connect the N-terminal
do-main to the serpin dodo-main by forming disulfide bridges with Cys183 and Cys406 (41). This deletion of 165 base pairs
pre-dicted a deletion of 55 amino acids of the N-terminal non-serpin domain, including two cysteines involved in the formation of the two disulfide bridges of the molecules. This mutant is further indicated as the⌬3 mutant.
Expression and Activity of C1-Inh Mutants—In the first in-stance it seemed unclear why the in-frame deletion identified in the patient should cause HAE; it is located outside the serpin domain, and earlier studies have indicated that the N-terminal domain is dispensable for inhibitory capacity (43). An explana-tion could be that the deleexplana-tion severely impedes secreexplana-tion, thereby explaining the type I form of HAE. Expression of the ⌬3 mutant in COS cells indicated, however, that the mutant was in fact secreted, albeit at lower levels than WT C1-Inh but
unable to form complexes with C1s. This suggested a disturbed functional interaction as the basis for disease, which is mostly associated with type II HAE. To assess in detail this impaired function of the N-terminal domain at a protein level, we de-cided to express and analyze several additional N-terminal deletion mutants, starting at amino acid 76, 98, and 115 (C1-Inh76, C1-Inh98, and C1-Inh115 respectively, summarized in
Fig. 2c). To obtain sufficient amounts of recombinant protein for a detailed analysis of the inhibitory and kinetic properties of the N-terminal deletion mutants, we produced WT, C1-Inh76,
C1-Inh98, and C1-Inh115in P. pastoris. In a previous study we
have shown that WT C1-Inh can be conveniently expressed in this system and is fully functionally active (50). The proteins were expressed at levels of 30, 35, 34, and 2g/ml, respectively. Supernatants of transfected cells or P. pastoris were ana-lyzed by ELISA for C1-Inh antigen and function. It appeared that the mutants ⌬3 and C1-INH115 were completely
non-functional toward C1s (Fig. 3), whereas C1-Inh76and C1-Inh98
displayed normal activity. Normal functional activity of the latter two mutants was confirmed in the kinetic analysis show-ing comparable association (kon) and dissociation (koff) con-stants of these mutants with C1s, kallikrein, and factor XIIa as WT C1-Inh (Table I). Thus, the decreased function of the⌬3 C1-Inh mutant likely was related to the absence of the linker sequence between the serpin domain and the N-terminal domain.
Heat Stability and Conformation of Normal and Mutant C1-Inh—Functional serpins, including C1-Inh, are in a meta-stable state that can be monitored by thermal unfolding of the protein. Serpins in a native conformation will precipitate or severely multimerize at elevated temperatures with concomi-tant loss of detectable antigen. However, upon inactivation by insertion of the reactive site loop into the central-sheet, a serpin will remain soluble. Although WT C1-Inh and the two N-terminal deletion mutants with intact disulfide bridges (C1-Inh76and C1-Inh98) were precipitated at 50 – 60 °C, C1-Inh115
and⌬3 remained detectable up to 80 °C (Fig. 4a). This indi-cated that the latter two mutant proteins are in an intrinsically stable conformation, as opposed to the metastable conforma-tion of the wild-type protein. This was confirmed by the in-creased reactivity of C1-Inh115and⌬3 with mAb Kok-12 (which
recognizes a neo-epitope exposed on complexed and inactivated C1-Inh) compared with WT, C1-Inh76, and C1-Inh98 C1-Inh.
Serial dilutions of C1-Inh were tested in the Kok-12 ELISA, and C1-Inh115and⌬3 displayed a profound reactivity with this
conformation-specific mAb (Fig. 4b). Notably, no reactivity of these two mutants with the mAb KII, specific for the cleaved form of C1-Inh, was observed (data not shown), which indicates that the mutants were not conformationally changed because of proteolytic cleavage of the reactive site loop.
Multimerization of Mutant C1-Inh in Vitro—Because in other C1-Inh mutants the intrinsic exposure of the Kok-12 epitope and an increase in heat stability were associated with spontaneous formation of non-covalent multimers (13, 35), WT C1-Inh or deletion mutants were analyzed in an ELISA de-signed to detect C1-Inh multimers. As can be observed in Fig. 5, the mutants ⌬3 and C1-Inh115 indeed appeared to form multimers in contrast with WT C1-Inh, C1-Inh76, and C1-Inh98. Multimers of⌬3 could also be observed upon size frac-tionation on sucrose gradients (results not shown). Together with the reactivity with mAb Kok-12 and the increased heat stability, these results suggested that the deletion mutant has a conformation similar to several C1-Inh mutants described previously, which was ascribed to overinsertion of the reactive site loop and/or release of strand 1C, resulting in multimer formation (13, 35).
FIG. 1. Low molecular mass C1-Inh is detected on SDS-PAGE
in affected HAE patient from a novel Dutch pedigree. Normal
(lane 2) and HAE plasma (lane 1) were absorbed onto RII-Sepharose, and bound C1-Inh was subjected to non-reducing 7.5% SDS-PAGE. After transfer to nitrocellulose, the blot was developed with polyclonal anti-C1-Inh antibodies.
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
Role of Disulfide Bridges in the Conformation of C1-Inh— Because the deletion encompasses only Cys101and Cys108, the
two remaining cysteines in the serpin domain might form a novel disulfide bond, which given the location of Cys183 and
Cys406would probably severely disturb the typical serpin
con-formation. To study the presence of disulfide bonds in the mutant protein, the normal and mutant proteins were
immu-noprecipitated with mAb RII and compared on reducing and non-reducing SDS-PAGE. In Fig. 6a it can be seen that the normal protein displayed a difference in apparent molecular mass upon reduction; under reducing conditions it migrated with an apparent molecular mass of 97 kDa, as has been observed before (e.g. Refs. 56, 57). The deletion mutant mi-grated at identical molecular mass under both conditions, and
FIG. 2. A mutation in exon 3 of the
C1-Inh gene deletes Asp62-Thr116 in the N-terminal, non-serpin domain of C1-Inh. a, PCR analysis of genomic DNA
of HAE patients with primers flanking exon 3 of the C1-Inh gene. Lanes 1 and 2 contain duplicate samples from an af-fected member of the family under inves-tigation. Lanes 3 and 4 represent an un-related HAE patient, displaying only the expected fragment at 997 base pairs. The
left lane contains a molecular mass
marker at 100-base pair increments. b, the nucleotide and derived amino acid se-quence of exon 3 of the C1-Inh gene. The serpin domain starts at His114. Bold
num-bers indicate amino acid residues
accord-ing to Bock et al. (41). The boxed area encloses the deletion of 165 base pairs found in this HAE pedigree. Repeats of the Glu-Pro-Thr-Thr sequence are doubly
underlined. The cysteines at positions 101
and 108 are indicated with bold italics.
c, schematic representation of four
differ-ent recombinant C1-Inh deletion mu-tants. The gray right part of each mutant represents the serpin domain of C1-Inh. The part of the N-terminal domain pres-ent in the various mutants is shown by
white bars on the left. A dotted line
repre-sents the linkage between Thr61
and Glu117in⌬3. The disulfide linkage
config-uration in WT C1-Inh is indicated by
dashed lines at the top.
C1-Inh Metastability Depends on Unique N-terminal Domain
29466
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
no disulfide-linked dimers could be observed (Fig. 6a, lanes 2 and 4), strongly arguing against the presence of novel intra- or intermolecular disulfide bonds.
Another possibility is that the absence of disulfide bridges itself caused the observed multimerization phenotype. We in-deed validated that permanent disruption of the disulfide bridges in normal C1-Inh by reduction and subsequent alkyla-tion led to intrinsic conformaalkyla-tional changes, as evidenced by formation of C1-Inh multimers. Shown in Fig. 6b is the exten-sive multimer formation at 37 °C for reduced/alkylated C1-Inh, whereas treatment with only alkylating reagent did not induce this state.
Conformation of Mutant C1-Inh in Vivo—To confirm the properties of the C1-Inh mutants, observed in vitro, in the naturally occurring situation, normal plasma and HAE plasma containing the deletion mutant were analyzed by size on su-crose gradients. To decrease the chance of activation and/or multimerization in vitro, for these experiments samples were used that had not been thawed previously. The fractions were tested in ELISAs for C1-Inh antigen and multimers (Fig. 7). Normal plasma displayed one peak in the C1-Inh antigen as-say, and no multimers were detected by ELISA. The plasma of the patient showed, in addition to a peak at the normal posi-tion, one or more peaks at fractions corresponding to higher molecular mass. Furthermore, only the patient plasma yielded a response in the multimer ELISA, at fractions corresponding to high molecular mass C1-Inh. Thus, the deletion mutant of C1-Inh is also secreted in vivo and circulates in a form that is, at least partially, multimeric.
DISCUSSION
Previously, we have described single-residue mutations in C1-Inh from HAE patients that cause a conformational change involving the reactive site loop and result in spontaneous mul-timer formation (13, 35) and/or dysfunction (40). Such point mutations, also observed in␣1-AT and ATIII (29, 36–38), are distributed over various regions of the serpin domain of C1-Inh (15). The mutation described here is peculiar, because it is not a point mutation of a highly conserved residue but a deletion of 55 residues in a domain that is unique for C1-Inh among the serpins. To investigate the effect of this deletion we produced several recombinant mutants, illustrated in Fig. 2c. While de-letion of the majority of this domain, i.e. up to 97 amino acid residues, had no effect on C1-Inh function, a deletion including the disulfide bridges of this part completely disrupted C1-Inh activity. Our observations may help understanding of the con-formational changes involved in C1-Inh function and the role of the N-terminal domain, including the cysteines that connect the serpin and the unique non-serpin domains in C1-Inh.
The phenotype of the C1-Inh mutant of the patient was a multimerization phenotype with no inhibitory activity. The⌬3 mutant as well as C1-Inh115both displayed strongly enhanced
reactivity in a multimer ELISA with a homologous sandwich of mAb RII (Fig. 5) and in an ELISA with mAb Kok-12 that reacts with neo-epitopes exposed on complexed or proteolytically cleaved C1-Inh (Fig. 4b). In other studies we have shown that the epitope for mAb Kok12 is also expressed on C1-Inh mul-timers (13). Notably, patient plasma contained circulating⌬3 multimers, as demonstrated with a sucrose gradient and a multimer ELISA (Fig. 7), ruling out that the observed multim-ers of the recombinant mutants were because of in vitro artifacts.
The affected members of the pedigree with the⌬3 C1-Inh mutant were described as type I HAE, based on their low C1-Inh antigen levels. This seems surprising when the effect on C1-Inh is considered to yield a dysfunctional protein, typically found in type II HAE. We hypothesize that the decreased levels of C1-Inh antigen leading to the diagnosis type I instead of type II result from varying mechanisms, including impaired secre-tion of the mutant protein. During recombinant expression of the C1-Inh115and⌬3 mutants we observed consistently lower
expression levels than for WT C1-Inh or the functional N-terminal deletion mutants. Metabolic labeling studies in COS cells were attempted without success to demonstrate intracel-lular localization, but multimers were detected in Western blots with cell extracts (data not shown). This suggests intra-cellular multimerization of these mutants in vitro as has been described for other C1-Inh variants of the multimerization phenotype (12, 13). However, the dysfunctional protein was also detected, though at low levels, in the plasma of the patient (Fig. 1). Although the clearance of serpin multimers in vivo has not been studied, that of complexed or inactivated serpins is increased compared with that of native serpins (54). Because C1-Inh multimers expose similar epitopes as complexes, as is demonstrated by the reactivity of mAb Kok12 (13), the clear-ance mechanism via the low density lipoprotein receptor-re-lated protein might be similar (58). This has in fact been experimentally supported by studies of Chang (59), who dem-onstrated competition between ␣1-AT and ATIII complexes versus multimers for binding to the low density lipoprotein receptor-related protein. Hence, increased clearance of the dys-functional mutant may have contributed to the apparent type I HAE phenotype.
The explanation for the observed multimerization phenotype can be the absence of the unique N-terminal domain and/or the absence of disulfide linkage between the N-terminal and the serpin domain. In a previous study (43), complex formation of truncated variants lacking amino acid 1–98 displayed the ca-pacity to form complexes with several target proteases that were stable for at least 30 min. To fully appreciate the conse-quences of the mutations, however, kinetic data are essential because complex formation does not necessarily imply full func-tional activity. Production of C1-Inh98 and C1-Inh76 in the
P. pastoris system yielded sufficient amounts of mutants for such detailed kinetic studies. We have shown before that WT C1-Inh from P. pastoris has similar kinetic properties as plas-ma-derived C1-Inh (51). Association and dissociation constants of the C1-Inh98 and C1-Inh76 mutants were essentially the same as for WT C1-Inh (see Table I). This definitely ruled out an essential role for the first 98 amino acids in inhibitory capacity of C1-Inh. It can, however, be postulated that the presence of the remaining part of the N-terminal domain of the⌬3 mutant pre-vents correct folding or function of the serpin domain. For that reason we produced C1-Inh115, which lacks the entire N-terminal domain and consists solely of the serpin domain. This mutant appeared to have the same phenotype as the⌬3 mutant identi-fied in the patient. This observation pointed to the absence of residues 99 to 115 as the explanation for the phenotype of the⌬3
FIG. 3. C1-Inh115and⌬3 mutants do not form complexes with C1s. Culture supernatants containing C1-Inh76, C1-Inh98, C1-Inh115,
⌬3 mutants, or WT C1-Inh were absorbed onto solid-phase mAb RII and incubated with biotinylated C1s. Functional activity was expressed as a percentage of activity in normal human plasma.
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
mutant rather than folding abnormalities induced by the remain-ing part of the N-terminal domain.
A feasible explanation for the observed inactivity is the dis-ruption of the disulfide bridges between Cys183and Cys406in
the serpin domain with, respectively, Cys108and Cys101in the
non-serpin domain. This may have at least two different ef-fects. First, the conformational change could result from a
novel disulfide bond between the remaining cysteines in the serpin domain, but SDS-PAGE analysis did not reveal a differ-ence in migration under reducing and non-reducing conditions (Fig. 6a). Because the effect of reduction and alkylation of plasma C1-Inh was similar to the effect of deletion of the two N-terminal cysteines (Fig. 6b) (42, 60),2it is most likely that
the absence of the disulfide linkage between the two domains had caused the inactivity of the ⌬3 mutant rather than the
2D. Roem and E. Eldering, unpublished observations.
TABLE I
Association (Kon) and dissociation (Koff) rate constants of C1-Inh with various target proteases, as determined with progress curves
Protease WT C1-Inh C1-Inh76 C1-Inh98
Kon⫻ (M⫺ 1s⫺1) K off Kon⫻ (M⫺ 1s⫺1) K off Kon⫻ (M⫺ 1s⫺1) K off Cls 6.3⫻ 104 2.3⫻ 10⫺5 6.5⫻ 104 2.5⫻ 10⫺5 4.4⫻ 104 1.0⫻ 10⫺5 Kallikrein 8.2⫻ 103 2.1⫻ 10⫺5 5.9⫻ 103 3.5⫻ 10⫺5 3.9⫻ 103 1.0⫻ 10⫺5 XIIa 5.7⫻ 103 1.4⫻ 10⫺5 5.2⫻ 103 1.0⫻ 10⫺6 1.6⫻ 103 1.2⫻ 10⫺5
FIG. 4. C1-INH115and⌬3 C1-Inh display a stable conformation.
a, heat stability. WT, C1-Inh76, C1-Inh98, C1-Inh115, and⌬3 C1-Inh
were incubated for 2 h at the indicated temperatures, centrifuged for 20 min at 10000⫻ g, and the supernatant was analyzed in the ELISA for C1-Inh antigen. b, C1-Inh preparations were analyzed in ELISA with Kok-12 as catching antibody. The detection of Kok-12 reactive C1-Inh was plotted against the C1-Inh concentration. Experiments were per-formed three times with similar results.
FIG. 5.⌬3 mutant forms multimers in vitro. The presence of C1-Inh multimers in supernatants containing WT C1-Inh or C1-Inh mutants was analyzed in a sandwich ELISA with mAb RII as both catching and detecting antibody. The detection of multimers is plotted against the C1-Inh concentration. The experiment was performed three times with similar results.
FIG. 6. Role of disulfide bonds in the conformation of C1-Inh. a,
absence of two cysteines does not lead to intra- or intermolecular disulfide bond formation. Normal (lanes 1 and 3) and mutant (lanes 2 and 4) C1-Inh from metabolically labeled transfection media were im-munoprecipitated with mAb RII and analyzed under non-reducing (lanes 1 and 2) or reducing (lanes 3 and 4) conditions on 10% SDS-PAGE. b, disruption of disulfide bonds in plasma C1-Inh causes mul-timerization. Control C1-Inh (lane 1 and 2) or reduced/alkylated C1-Inh (lane 3 and 4) was incubated for 2 h at 37 °C (lane 1 and 3) or 60 °C (lane
2 and 4)at a concentration of 1 mg/ml. Samples were analyzed by 4 –15%
native PAGE.
C1-Inh Metastability Depends on Unique N-terminal Domain
29468
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
presence of an intra-serpin domain disulfide bond. This inter-pretation is entirely in line with earlier results demonstrating that disruption of the disulfide bridges in full-length C1-Inh results in the formation of a latent, inactive conformation (59). Our results demonstrating the crucial role of residues 99 to 115 underline the importance of the disulfide bonds in the stabili-zation of the active conformation of C1-Inh. The crucial role of the cysteines for serpin metastability is surprising because these residues are not conserved among the serpins.
We have previously put forward a 3-dimensional model of the serpin domain of C1-Inh based on homology with the crystal structures of four native serpins (14). Comparison of the posi-tions of the disulfide bonds in this model (Fig. 8a) with the structure of ATIII complexed to a pentasaccharide reveals an interesting homology (Fig. 8b) (61). Native ATIII has a flexible central-sheet with the reactive site loop partly inserted. Bind-ing of a pentasaccharide closes the central -sheet, thereby stabilizing the metastable conformation and expelling the re-active site loop, resulting in potentiation of ATIII. Moreover, it is known that the presence of the pentasaccharide inhibits spontaneous auto-insertion of the reactive site loop of ATIII (61). The heparin-binding region on ATIII is located in the same region as Cys183in C1-Inh (42). This suggests that the
N-terminal domain of C1-Inh linked via disulfide bridges to the serpin domain has a similar function as heparin for ATIII, which is stabilization of the central -sheet to maintain the metastable conformation. Notably, ATIII without heparin is less stable than C1-Inh and latent ATIII is observed in plasma, whereas latent C1-Inh has never been observed in vivo or in vitro (28). Several other mutations leading to HAE support the importance of this region for the metastable conformation of C1-Inh. First, mutation of the residues Gly1623 Glu/Arg and
Thr1693 Pro leads to type I HAE (62, 63). These residues are
located between Cys183and Cys406, and their mutation might
also affect stability of the central-sheet. Secondly, mutation of Cys1833 Tyr leads to type I HAE (63). The second cysteine
in the serpin domain of C1-Inh (Cys406) is located at the same
site as the disulfide bridge that links the short N-terminal domain of ATIII to the serpin domain (Cys21 to Cys95). This
suggests that the terminal part of the unique N-terminal do-main of C1-Inh is located at a similar position as the short N-terminal domain of ATIII. Taken together these data strongly suggest that the role of the disulfide bridges in C1-Inh is similar to that of heparin binding for ATIII. However, whereas the activity of ATIII is functionally regulated by hep-arin at these sites, active conformation of C1-Inh would be constitutively primed by the geometrical constraints imposed
by the disulfide bridges in the context of residues 99 to 115 of its N-terminal domain. The inhibitory activity of C1-Inh, en-hanced by heparin and other highly negatively charged poly-mers (64, 65), must therefore be potentiated through a different mechanism than that of ATIII.
CONCLUSIONS
A novel pathological C1-Inh mutant with a deletion of 55 amino acids in the unique N-terminal domain of C1-Inh was identified. Studies of a recombinant variant of this mutant and N-terminal deletion mutants starting at amino acids 76, 98, and 115 indicated that C1-Inh115 and⌬3 C1-Inh displayed a
conformational change leading to multimerization, whereas C1-Inh76and C1-Inh98displayed a wild-type-like conformation. The⌬3 C1-Inh and the C1-Inh115mutants were dysfunctional
FIG. 7. Presence of C1-Inh multimers in vivo. Samples (200l) of
normal (NP, closed symbols) or mutant HAE (D3, open symbols) plasma were layered onto 5–25% sucrose gradients. Fractions were analyzed in C1-Inh antigen (circles) and multimer (triangles) ELISA. For C1-Inh antigen ELISA, NP fractions were diluted 1:100, D3 fractions were diluted 1:50, and the dilution for the multimer ELISA was 1:25. The IgG peak as determined by nephelometric analysis was in fraction 27.
FIG. 8. Structure of C1-Inh compared with that of
ATIII-pen-tasaccharide complex. a, homology model of C1-Inh based on the
crystal structure of four different active serpins (14). The N-terminal Thr116
and the two cysteines in the serpin domain are indicated as
ball-and-stick and labeled. b, crystal structure of ATIII bound to a
pentasaccharide (1AZX (61) from the Protein Database (www.rcsb.org/ pdb/) viewed in WebLabViewerLite (www.msi.com)). Phe121and Cys95
of ATIII, at the same location as Cys183
and Cys406
of C1-Inh, are indicated as ball-and-stick and labeled. The pentasaccharide is also indicated as ball-and-stick and labeled.
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
because the absence of the disulfide bridges between the serpin and the unique N-terminal domain led to destabilization of the metastable conformation of the serpin domain. This stabilizing function of the N-terminal domain of C1-Inh resembles that of heparin for ATIII. Thus, a broader perspective is offered for understanding aberrant protein folding and/or multimeriza-tion by intermolecular-sheet interactions, leading to pathol-ogies which include HAE, emphysema, Alzheimer’s, and the prion encephalopathies.
Acknowledgment—We thank H. Tonie Wright (Dept. of Biochemistry
and Molecular Biophysics, Virginia Commonwealth University, Rich-mond, VA) for contributions and helpful discussions concerning serpin structure in an early phase of the study.
REFERENCES
1. Donaldson, V. H., and Evans, R. R. (1963) Am. J. Med. 35, 37– 44 2. Cooper, N. R. (1985) Adv. Immunol. 37, 151–216
3. Sim, R. B., Reboul, A., Arlaud, G. J., Villiers, C. L., and Colomb, M. G. (1979)
FEBS Lett. 97, 111–115
4. Pixley, R. A., Schapira, M., and Colman, R. W. (1985) J. Biol. Chem. 260, 1723–1729
5. van der Graaf, F., Koedam, J. A., and Bouma, B. N. (1983) J. Clin. Invest. 71, 149 –158
6. Schapira, M., Scott, C. F., and Colman, R. W. (1982) J. Clin. Invest. 69, 462– 468
7. Schapira, M., de Agostini, A., Schifferli, J. A., and Colman, R. W. (1985)
Complement 2, 111–126
8. Chan, J. Y., Burrowes, C. E., Habal, F. M., and Movat, H. Z. (1977) Biochem.
Biophys. Res. Commun. 74, 150 –158
9. Wuillemin, W. A., Minnema, M., Meijers, J. C., Roem, D., Eerenberg, A. J., Nuijens, J. H., ten Cate, H., and Hack, C. E. (1995) Blood 85, 1517–1526 10. Davis, A. E. (1988) Annu. Rev. Immunol. 6, 595– 628
11. Quastel, M., Harrison, R., Cicardi, M., Alper, C. A., and Rosen, F. S. (1983)
J. Clin. Invest. 71, 1041–1046
12. Verpy, E., Couture-Tosi, E., Eldering, E., Lopez-Trascasa, M., Spath, P., Meo, T., and Tosi, M. (1995) J. Clin. Invest. 95, 350 –359
13. Eldering, E., Verpy, E., Roem, D., Meo, T., and Tosi, M. (1995) J. Biol. Chem.
270, 2579 –2587
14. Bos, I. G., Hack, C. E., and Abrahams, J. P. (2002) Immunobiology 205, 518 –533
15. Stein, P. E., and Carrell, R. W. (1995) Nat. Struct. Biol. 2, 96 –113 16. Wright, H. T., and Scarsdale, J. N. (1995) Proteins 22, 210 –225
17. Huntington, J. A., Read, R. J., and Carrell, R. W. (2000) Nature 407, 923–926 18. Kaslik, G., Patthy, A., Balint, M., and Graf, L. (1995) FEBS Lett. 370, 179 –183 19. Stavridi, E. S., O’Malley, K., Lukacs, C. M., Moore, W. T., Lambris, J. D., Christianson, D. W., Rubin, H., and Cooperman, B. S. (1996) Biochemistry
35, 10608 –10615
20. Wright, H. T., and Blajchman, M. A. (1994) FEBS Lett. 348, 14 –16 21. Lawrence, D. A., Olson, S. T., Palaniappan, S., and Ginsburg, D. (1994) J. Biol.
Chem. 269, 27657–27662
22. Hood, D. B., Huntington, J. A., and Gettins, P. G. (1994) Biochemistry 33, 8538 – 8547
23. Hopkins, P. C., and Stone, S. R. (1995) Biochemistry 34, 15872–15879 24. Gils, A., Knockaert, I., and Declerck, P. J. (1996) Biochemistry 35, 7474 –7481 25. Davis, A. E., Aulak, K., Parad, R. B., Stecklein, H. P., Eldering, E., Hack, C. E., Kramer, J., Strunk, R. C., Bissler, J., and Rosen, F. S. (1992) Nat. Genet. 1, 354 –358
26. Levy, N. J., Ramesh, N., Cicardi, M., Harrison, R. A., and Davis, A. E. (1990)
Proc. Natl. Acad. Sci. U. S. A. 87, 265–268
27. Mottonen, J., Strand, A., Symersky, J., Sweet, R. M., Danley, D. E., Geoghe-gan, K. F., Gerard, R. D., and Goldsmith, E. J. (1992) Nature 355, 270 –273 28. Carrell, R. W., Huntington, J. A., Mushunje, A., and Zhou, A. (2001) Thromb.
Haemostasis 86, 14 –22
29. Lomas, D. A., Evans, D. L., Stone, S. R., Chang, W. S., and Carrell, R. W. (1993)
Biochemistry 32, 500 –508
30. Lomas, D. A., Elliott, P. R., Chang, W. S., Wardell, M. R., and Carrell, R. W. (1995) J. Biol. Chem. 270, 5282–5288
31. Carrell, R. W., Stein, P. E., Fermi, G., and Wardell, M. R. (1994) Structure 2, 257–270
32. Mast, A. E., Enghild, J. J., and Salvesen, G. (1992) Biochemistry 31, 2720 –2728
33. Patston, P. A., Hauert, J., Michaud, M., and Schapira, M. (1995) FEBS Lett.
368, 401– 404
34. Lomas, D. A., and Carrell, R. W. (2002) Nat. Rev. Genet. 3, 759 –768 35. Aulak, K. S., Eldering, E., Hack, C. E., Lubbers, Y. P., Harrison, R. A., Mast,
A., Cicardi, M., and Davis, A. E. (1993) J. Biol. Chem. 268, 18088 –18094 36. Lindo, V. S., Kakkar, V. V., Learmonth, M., Melissari, E., Zappacosta, F.,
Panico, M., and Morris, H. R. (1995) Br. J. Haematol. 89, 589 – 601 37. Lomas, D. A., Finch, J. T., Seyama, K., Nukiwa, T., and Carrell, R. W. (1993)
J. Biol. Chem. 268, 15333–15335
38. Lomas, D. A., Elliott, P. R., Sidhar, S. K., Foreman, R. C., Finch, J. T., Cox, D. W., Whisstock, J. C., and Carrell, R. W. (1995) J. Biol. Chem. 270, 16864 –16870
39. Bruce, D., Perry, D. J., Borg, J. Y., Carrell, R. W., and Wardell, M. R. (1994)
J. Clin. Invest. 94, 2265–2274
40. Zahedi, R., Aulak, K. S., Eldering, E., and Davis, A. E. (1996) J. Biol. Chem.
271, 24307–24312
41. Bock, S. C., Skriver, K., Nielsen, E., Thogersen, H. C., Wiman, B., Donaldson, V. H., Eddy, R. L., Marrinan, J., Radziejewska, E., and Huber, R. (1986)
Biochemistry 25, 4292– 4301
42. Simonovic, I., and Patston, P. A. (2000) Biochim. Biophys. Acta 1481, 97–102 43. Coutinho, M., Aulak, K. S., and Davis, A. E. (1994) J. Immunol. 153,
3648 –3654
44. Nuijens, J. H., Huijbregts, C. C., van Mierlo, G. M., and Hack, C. E. (1987)
Immunology 61, 387–389
45. Nuijens, J. H., Huijbregts, C. C., Eerenberg-Belmer, A. J., Abbink, J. J., Strack, v. S. R., Felt-Bersma, R. J., Thijs, L. G., and Hack, C. E. (1988)
Blood 72, 1841–1848
46. Dykes, D. D. (1988) Electrophoresis 9, 359 –368
47. Cugno, M., Nuijens, J., Hack, E., Eerenberg, A., Frangi, D., Agostoni, A., and Cicardi, M. (1990) J. Clin. Invest. 85, 1215–1220
48. Carter, P. E., Duponchel, C., Tosi, M., and Fothergill, J. E. (1991) Eur. J.
Bio-chem. 197, 301–308
49. Verpy, E., Biasotto, M., Brai, M., Misiano, G., Meo, T., and Tosi, M. (1996)
Am. J. Hum. Genet. 59, 308 –319
50. Eldering, E., Nuijens, J. H., and Hack, C. E. (1988) J. Biol. Chem. 263, 11776 –11779
51. Bos, I. G., de Bruin, E. C., Karuntu, Y. A., Modderman, P. W., Eldering, E., and Hack, C. E. (2003) Biochim. Biophys. Acta 1648, 75– 83
52. Nuijens, J. H., Eerenberg-Belmer, A. J., Huijbregts, C. C., Schreuder, W. O., Felt-Bersma, R. J., Abbink, J. J., Thijs, L. G., and Hack, C. E. (1989) J. Clin.
Invest. 84, 443– 450
53. Bos, I. G., van Mierlo, G. J., Bleeker, W. K., Rigter, G. M., te Velthuis, H., Dickneite, G., and Hack, C. E. (2001) Int. Immunopharmacol. 1, 1583–1595 54. de Smet, B. J., de Boer, J. P., Agterberg, J., Rigter, G., Bleeker, W. K., and
Hack, C. E. (1993) Blood 81, 56 – 61
55. Eldering, E., Huijbregts, C. C., Lubbers, Y. T., Longstaff, C., and Hack, C. E. (1992) J. Biol. Chem. 267, 7013–7020
56. Pemberton, P. A., Harrison, R. A., Lachmann, P. J., and Carrell, R. W. (1989)
Biochem. J. 258, 193–198
57. Schoenberger, O. L., Sprows, J. L., Schechter, N. M., Cooperman, B. S., and Rubin, H. (1989) FEBS Lett. 259, 165–167
58. Storm, D., Herz, J., Trinder, P., and Loos, M. (1997) J. Biol. Chem. 272, 31043–31050
59. Chang, W. S. (1995) Conformational Mobility and Interactions of the Serpins. Ph.D. thesis, Cambridge University, Cambridge, UK
60. Nilsson, T., and Wiman, B. (1982) Biochim. Biophys. Acta 705, 271–276 61. Jin, L., Abrahams, J. P., Skinner, R., Petitou, M., Pike, R. N., and Carrell,
R. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14683–14688
62. Bissler, J. J., Aulak, K. S., Donaldson, V. H., Rosen, F. S., Cicardi, M., Harrison, R. A., and Davis, A. E. (1997) Proc. Assoc. Am. Physicians 109, 164 –173
63. Zuraw, B. L., and Herschbach, J. (2000) J. Allergy Clin. Immunol. 105, 541–546
64. Rent, R., Myhrman, R., Fiedel, B. A., and Gewurz, H. (1976) Clin. Exp.
Immunol. 23, 264 –271
65. Wuillemin, W. A., te Velthuis, H., Lubbers, Y. T., de Ruig, C. P., Eldering, E., and Hack, C. E. (1997) J. Immunol. 159, 1953–1960
C1-Inh Metastability Depends on Unique N-terminal Domain
29470
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
Hack and Eric Eldering
Ineke G. A. Bos, Yvonne T. P. Lubbers, Dorina Roem, Jan Pieter Abrahams, C. Erik
Unique N-terminal Domain, as Revealed by a Pathological Mutant
The Functional Integrity of the Serpin Domain of C1-inhibitor Depends on the
doi: 10.1074/jbc.M302977200 originally published online May 27, 2003
2003, 278:29463-29470.
J. Biol. Chem.
10.1074/jbc.M302977200
Access the most updated version of this article at doi:
Alerts:
When a correction for this article is posted
•
When this article is cited
•
to choose from all of JBC's e-mail alerts
Click here
http://www.jbc.org/content/278/32/29463.full.html#ref-list-1
This article cites 64 references, 19 of which can be accessed free at
at WALAEUS LIBRARY on May 4, 2017
http://www.jbc.org/
